





How to manage viral blip discussions

MARK FISHER

MARK@BODYPOSITIVE.ORG.NZ

WHAT'S A BLIP?

A **blip** is when the viral load temporarily rises to a detectable level.



If you have questions about blips, talk to your health care provider.



Frequent blips can be a sign of trouble. But occasional blips can happen to anyone with HIV. **An occasional blip doesn't mean that your HIV treatment is failing.**



Blips can happen when your immune system is under stress, for example, when you're sick.



Skipping doses of HIV medicines can also cause blips. Taking your medicines every day can help prevent blips. Keeping your viral load under control is key to a longer, healthier life with HIV.

For more information, visit HIVinfo.NIH.gov.



THE ROLE OF HIV VIRAL SUPPRESSION IN IMPROVING INDIVIDUAL HEALTH AND REDUCING TRANSMISSION

POLICY BRIEF



22 July 2023



The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review

Laura N Broyles, Robert Luo, Debi Boeras, Lara Vojnov

Summary


Background The risk of sexual transmission of HIV from individuals with low-level HIV viraemia receiving antiretroviral therapy (ART) has important public health implications, especially in resource-limited settings that use alternatives to plasma-based viral load testing. This Article summarises the evidence related to sexual transmission of HIV at varying HIV viral load levels to inform messaging for people living with HIV, their partners, their health-care providers, and the wider public.

Findings 244 studies were identified and eight were included in the analysis, comprising 7762 serodiscordant couples across 25 countries. The certainty of evidence was moderate; the risk of bias was low. Three studies showed no HIV transmission when the partner living with HIV had a viral load less than 200 copies per mL. Across the remaining four prospective studies, there were 323 transmission events; none were in patients considered stably suppressed on ART. Among all studies there were two cases of transmission when the index patient's (ie, patient with previously diagnosed HIV infection) most recent viral load was less than 1000 copies per mL. However, interpretation of both cases was complicated by long intervals (ie, 50 days and 53 days) between the transmission date and the most recent index viral load result.

Interpretation There is almost zero risk of sexual transmission of HIV with viral loads of less than 1000 copies per mL. These data provide a powerful opportunity to destigmatise HIV and promote adherence to ART through dissemination of this positive public health message. These findings can also promote access to viral load testing in resource-limited settings for all people living with HIV by facilitating uptake of alternative sample types and technologies.

Funding Bill & Melinda Gates Foundation.


Unsuppressed Suppressed
but detectable Undetectable



- 1 Undetectable (not detected*):**
no measurable virus. Zero risk of transmission to sexual partner(s); minimal risk of mother to child transmission.
- 2 Suppressed (detected but ≤ 1000 copies/mL):**
some virus replicating and present: could be due to missing doses, recent treatment initiation or drug resistance. Almost zero or negligible risk of transmission to sexual partner(s).
- 3 Unsuppressed (>1000 copies/mL):**
significant virus replicating and present: could be due to missing doses, recent treatment initiation or drug resistance. Increased risk of falling ill and/or passing virus on to sexual partner(s) or children.

The ultimate goal for all people living with HIV is to reach and sustain **undetectable** viral loads. Taking antiretroviral therapy as prescribed will support this goal, prevent transmission to their sexual partner(s) and/or children, and improve their own clinical well-being.

* Not detected by the test or sample type used.



Without antiretroviral therapy, median viral load values tend to be considerable: anywhere from 30 000 to >500,000 copies/ mL, depending on the stage of infection

Diagnosed, untreated

Undiagnosed

HIV RNA Assay	VL Lower Limit of Detection, Copies/mL	Results Reported for Low VL Values
Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0 ^a	20	“HIV-1 RNA not detected” “HIV-1 RNA detected, <20 HIV-1 RNA copies/mL”
bioMérieux NucliSENS EasyQ HIV-1 v2.0 ^b	10	“Target not detected” “<10 copies/mL”
Abbott RealTime HIV-1 Viral Load Assay ^b	40	“Not detected” “<40 copies/mL”
Hologic Aptima HIV-1 Quant Dx Assay ^c	30	“Not detected” “<30 detected”



200 copies /ml



Undetectable

90 80 70 60

100 <LOD <LLOQ 50

10 20 30 40





When U=U isn't so simple: How viral blips can affect your viral load

So, you can imagine
it came as quite a shock
when I had a phone call from my doctor
who informed me that my viral load
was no longer undetectable.



Undetectable viral load & treatment as prevention

Giving a figure for HIV viral load below 200 is a “harmful medical practice”

Roger Pebody | 2 January 2024 | Estimated reading time 4 minutes

JOURNAL ARTICLE EDITOR'S CHOICE

The Perils of Overly Sensitive Viral Load Testing for Persons With Human Immunodeficiency Virus

Maria G Rodriguez , Alina Syros , Allan E Rodriguez , David P Serota  [Author Notes](#)

Open Forum Infectious Diseases, Volume 10, Issue 10, October 2023, ofad494,
<https://doi.org/10.1093/ofid/ofad494>

Published: 03 October 2023 **Article history** ▼

Health New Zealand | Te Whatu Ora

26 March 2024

Health New Zealand
Te Whatu Ora



DHA

TE RŌPŪ
HAUORA
MATIHIKO

Digital Health Association

Addressing the harms of
reporting detectable viral
loads <200 copies/mL

```
graph TD; A([Addressing the harms of reporting detectable viral loads <200 copies/mL]) --> B[Counseling]; A --> C[Laboratory]; A --> D[Research];
```

Counseling

Education that VL <200 is undetectable with regards to infectiousness

Using the teaching point that "our treatment goal is VL <200 and CD4 >200"

Laboratory


Reporting an interpretation of "no risk of sexual transmission" for VL <200

Reporting all VLs between the LLD and 200 as not detected

Research

Studies evaluating how different VL reporting practices impact physician actions, patient experience, and clinical outcomes

VIRAL LOAD



If you have questions about blips, talk to your health care provider.

sign of trouble. But
open to anyone with HIV.
It doesn't mean that your HIV

can happen when your
system is under stress,
for example, when you're sick.


HIV medicines can also cause
side effects. Taking medicines every day can help
keep your viral load under
control, for a longer, healthier life with HIV.

Suppressed
but detectable



2 Suppressed (detected but ≤ 1000 copies/mL):

Almost Zero, or negligible risk
of transmission to sexual
partners



```
graph TD; A([Addressing the harms of reporting detectable viral loads <200 copies/mL]) --> B[Counseling]; A --> C[Laboratory]; A --> D[Research];
```

Addressing the harms of
reporting detectable viral
loads <200 copies/mL

Counseling

Education that VL <200
is undetectable with
regards to infectiousness

Using the teaching point
that "our treatment goal
is VL <200 and CD4
>200"

Laboratory

Reporting an
interpretation of "no risk
of sexual transmission"
for VL <200

Reporting all VLs
between the LLD and
200 as not detected

Research

Studies evaluating how
different VL reporting
practices impact
physician actions, patient
experience, and clinical
outcomes

Addressing the harms of
reporting detectable viral
loads <1000 copies/mL

```
graph TD; A([Addressing the harms of reporting detectable viral loads <1000 copies/mL]) --> B[Counseling]; A --> C[Laboratory]; A --> D[Research];
```

Counseling

Education that VL <1000
is **supressed** with
regards to infectiousness
Using the teaching point
that our treatment goal
is VL <1000

Laboratory

Reporting an
interpretation of <1000
as negligible risk of
sexual transmission
Reporting all VLs
between 200 and
1000 as **supressed**

Research

Studies evaluating how
different VL reporting
practices impact
physician actions, patient
experience, and clinical
outcomes

**MY BOYFRIEND IS
LIVING WITH HIV
I'M NOT BECAUSE HE
CAN'T PASS IT ON**



Good Adherence, communication, trust

A word cloud on a gray background with the word "stigma" as the central, largest term. Other words are arranged around it in various sizes and colors (blue, dark blue, and gray). The words represent factors that can lead to medication resistance or non-adherence.

treatment-holidays
incorrect-regimens
drug-stockouts
cost/affordability
poor-adherence
drug-interactions
substance-use
mental-health
stigma
Access
Adherence
side-effects
treatment-interruptions
healthcare-stigma
inadequate-dosing

Blips vs
Resistance

7.2 Blips

- In individuals on ART, a single viral load of 50–200 copies/mL preceded and followed by an undetectable viral load is usually not a cause for clinical concern (GPP). It should necessitate clinical vigilance, adherence reinforcement, a search for possible interactions and repeat testing within 2–6 weeks depending on ARV regimen.

7.3 Low-level viraemia on ART

- We recommend that in the context of low-level viraemia or repeated viral blips, resistance testing should be attempted (Grade 1D).
- We recommend that in the context of low-level viraemia or repeated blips a high genetic barrier regimen should be used (GPP).